Adlai Nortye Group: Only For The Risk-Tolerant After A Massive Rally

Adlai Nortye Group, a biopharmaceutical company, has seen its share price rise significantly in recent months.

The company is developing a pipeline of cancer treatments, but its stock is considered high-risk due to its early-stage status.